Familial primary hypomagnesemia with hypocalcuria
diseaseOn this page
Summary
Familial primary hypomagnesemia with hypocalcuria (MONDO:0017625) is a disease and 1 clinical trial. A subtype of familial primary hypomagnesemia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 1
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | familial primary hypomagnesemia with hypocalcuria |
| Mondo ID | MONDO:0017625 |
| Orphanet | 306519 |
| SNOMED CT | 711151004 |
| GARD | 0025120 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of familial primary hypomagnesemia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › inborn errors of metabolism › inborn metal metabolism disorder › familial primary hypomagnesemia › familial primary hypomagnesemia with hypocalcuria
Related subtypes (4): familial primary hypomagnesemia with hypercalciuria and nephrocalcinosis, familial primary hypomagnesemia with normocalcuria, EGF-related primary hypomagnesemia with intellectual disability, hypomagnesemia 7, renal, with or without dilated cardiomyopathy
Subtypes (1): renal hypomagnesemia 2
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 1.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06065852 | Not specified | RECRUITING | National Registry of Rare Kidney Diseases |
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.